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Secondary	Outcome	 	30mg	 75mg	 125mg	
Mean	BDI-II	score	
Change†	 –4·6	(8·8)	 –15·4	(9·5)	 –24·6	(10·6)	
p	value‡	 NA	 0·052	 0·0003	
Mean	PSQI	
Change†	 1·8	(2·8)	 –6·4	(7·1)	 –4·8	(4·1)	
p	value‡	 NA	 0·01	 0·02	
Mean	PTGI	score	
Change†	 –11·6	(12·2)	 36·1	(12·0)	 33·7	(24·0)	
p	value‡	 NA	 <0·0001	 <0·0001	
Mean	GAF	score	
Change†	 1·1	(4·6)	 19·4	(6·1)	 18·4	(14·4)	
p	value‡	 NA	 0·004	 0·002	
Mean	DES-II	score	
Change†	 1·8	(0·9)	 –8·6	(1·9)	 –8·8	(6·2)	
p	value‡	 NA	 0·02	 0·01	
Mean	NEO-PI-R	score	
Neuroticism	
Change†	 –4·6	(5·5)	 –12·0	(3·6)	 –16·5	(11·8)	
p	value‡	 NA	 0·23	 0·03	
Extroversion	
Change†	 2·2	(4·3)	 10·0	(9·4)	 8·0	(9·4)	
p	value‡	 NA	 0·17	 0·22	
Openness	
Change†	 –0·6	(9·9)	 15·6	(5·3)	 2·0	(10·5)	
p	value‡	 NA	 0·02	 0·62	
Agreeableness	
Change†	 –1·2	(8·4)	 5·4	(8·0)	 5·9	(4·9)	
p	value‡	 NA	 0·13	 0·05	
Conscientiousness	
Change†	 –3·2	(7·9)	 2·4	(15·0)	 6·5	(13·4)	


















































































































-11.5	(21.2)	 N/A	 -4	(11.9)	 N/A	
100mg	(active	
dose)	
-24.4	(24.2)	 0.36	 -24.4	(24.2)	 0.10	
125mg	(active	
dose)	






































BDI-II	change,		mean	(SD)	 -11.5	(7.8)	 -9.9	(13.3)	 -11	(13.7)	
PSQI	change,			mean	(SD)	 -0.8	(2.5)	 -3.6	(6.2)	 -2.0	(4.7)	









































































































































































































































































Appendix A: CAPS DSM-V 
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